Antibiotic resistance and the potential impact of pneumococcal conjugate vaccines
DOI:
https://doi.org/10.33321/cdi.2003.27.37Keywords:
Streptococcus pneumoniae, antibiotic resistance, pneumococcal conjugate vaccine, PNCRM7Abstract
Streptococcus pneumoniae is a major cause of morbidity and mortality in young children throughout the world, causing both invasive (meningitis, bacteraemia) and non-invasive (pneumonia, acute otitis media, sinusitis) infections. Over the past few decades, the global emergence of antibiotic-resistant pneumococcal strains has complicated disease management. Thus, healthcare practitioners have begun to place more emphasis on the judicious use of antibiotics and prevention of disease through routine immunisation. Researchers have developed several pneumococcal conjugate vaccines, which due to their technology, are effective in infants and young children. Currently, one 7-valent pneumococcal conjugate vaccine (PNCRM7; Prevenar®, Wyeth) is available in various parts of the world and has demonstrated excellent efficacy against vaccine-type invasive disease and efficacy against pneumonia and otitis media caused by the serotypes included in the vaccine. Furthermore, there is evidence suggesting that the use of these conjugate vaccines will reduce the need for antibiotics and the subsequent spread of antibiotic-resistant pneumococci. Ultimately, when routine pneumococcal conjugate vaccination of infants and young children is accompanied by supportive education and active disease surveillance as well as judicious use of antibiotics, there should be a favourable impact on pneumococcal disease incidence in and beyond the vaccinated population. Commun Dis Intell 2003;27 Suppl:S134-S142.
Downloads
References
Van Beneden CA, Whitney CG, Levine OS. Preventing pneumococcal disease among infants and young children. MMWR Morb Mortal Wkly Rep 2000;49:1-38.
Black S, Shinefield H, Fireman B, Lewis E, Ray P, Hansen JR, et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group. Pediatr Infect Dis J 2000;19:187-95.
McIntyre PB, Gilmour RE, Gilbert GL, Kakakios AM, Mellis CM. Epidemiology of invasive pneumococcal disease in urban New South Wales, 1997-1999. Med J Aust 2000;173 Suppl:S22-S26.
Torzillo PJ, Hanna JN, Morey F, Gratten M, Dixon J, Erlich J, et al. Invasive pneumococcal disease in Central Australia. Med J Aust 1995;162:182-186.
Fagan RL, Hanna JN, Messer RD, Brookes DL, Murphy DM. The epidemiology of invasive pneumococcal disease in children in Far North Queensland. J Paediatr Child Health 2001;37:571-575.
Hogg GG, Strachan JE, Lester RA. Invasive pneumococcal disease in the population of Victoria. Med J Aust 2000;173 Suppl:S32-S35.
Liddle JL, McIntyre PB, Davis CW. Incidence of invasive pneumococcal disease in Sydney children, 1991-96. J Paediatr Child Health 1999;35:67-70.
Dowell SF, Schwartz B. Resistant pneumococci: protecting patients through judicious use of antibiotics. Am Fam Physician 1997;55:1647-1648.
Collignon PJ, Turnidge JD. Antibiotic resistance in Streptococcus pneumoniae. Med J Aust 2000;173 Suppl:S58-S64.
Hausdorff WP, Bryant J, Paradiso PR, Siber GR. Which pneumococcal serogroups cause the most invasive disease: implications for conjugate vaccine formulation and use, part I. Clin Infect Dis 2000;30:100-121.
Gratten M, Carlisle J, Hanna J, Bapty G, George N, Nuttall N, et al. Seroepidemiology of invasive pneumococcal disease in Queensland, 1990 to 1997. Commun Dis Intell 1998;22:265-269.
Butler JC, Bulkow LR, Parks DJ, et al. Epidemiology of pneumococcal bacteremia and meningitis during the first 5 years of life in Alaska: implications for conjugate pneumococcal vaccine use [abstract]. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy 2000;672.
Syrjänen R, Kilpi T, Herva E, et al. Pneumococcal carriage during health and respiratory infection [abstract]. International Symposium on Pneumococci and Pneumococcal Disease Abstract Book 1998;29.
Appelbaum PC, Gladkova C, Hryniewicz W, Kojouharov B, Kotulova D, Mihalcu F, et al. Carriage of antibiotic-resistant Streptococcus pneumoniae by children in eastern and central Europe-a multi-center study with use of standardized methods. Clin Infect Dis 1996;23:712-717.
Garcia-de-Lomas J, Gimeno C, Millas E, Bermejo M, Lazaro MA, Navarro D, et al. Antimicrobial susceptibility of Streptococcus pneumoniae isolated from pediatric carriers in Spain. Eur J Clin Microbiol Infect Dis 1997;16:11-13.
Shackley F, Heath PT, Diggle L, et al. Carriage of Streptococcus pneumoniae (Spn) in Oxford children [abstract]. International Symposium on Pneumococci and Pneumococcal Diseases 1998;36.
Skull SA, Shelby-James T, Morris PS, Perez GO, Yonovitz A, Krause V, et al. Streptococcus pneumoniae antibiotic resistance in Northern Territory children in day care. J Paediatr Child Health 1999;35:466.
Nasrin D, Collignon PJ, Roberts L, Wilson EJ, Pilotto LS, Douglas RM. Effect of beta-lactam antibiotic use in children on pneumococcal resistance to penicillin: prospective cohort study. BMJ 2002;324:28-30.
Butler JC, Dowell SF, Breiman RF. Epidemiology of emerging pneumococcal drug resistance: implications for treatment and prevention. Vaccine 1998;16:1693-1697.
Gosbell IB, Neville SA. Antimicrobial resistance in Streptococcus pneumoniae: a decade of results from south-western Sydney. Commun Dis Intell 2000;24:340-343.
National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing; 11th informational supplement. National Committee for Clinical Laboratory Standards, Wayne, Pennsylvania, 2001;21:1-123.
American Academy of Paediatrics Committee on Infectious Diseases. Therapy for children with invasive pneumococcal infections. Paediatrics 1997;99:289-299.
Fenoll A, Martin BC, Munoz R, Vicioso D, Casal J. Serotype distribution and antimicrobial resistance of Streptococcus pneumoniae isolates causing systemic infections in Spain, 1979-1989. Rev Infect Dis 1991;13:56-60.
Fenoll A, Jado I, Vicioso D, Berron S, Yuste JE, Casal J, et al. Streptococcus pneumoniae in children in Spain: 1990-1999. Acta Paediatr 2000;89 Suppl:44-50.
Doern GV, Pfaller MA, Kugler K, Freeman J, Jones RN. Prevalence of antimicrobial resistance among respiratory tract isolates of Streptococcus pneumoniae in North America: 1997 results from the SENTRY antimicrobial surveillance program. Clin Infect Dis 1998;27:764-770.
Turnidge JD, Bell JM, Collignon PJ. Rapidly emerging antimicrobial resistance in Streptococcus pneumoniae in Australia. Med J Aust 1999;170:152-155.
Jacobs MR, Bajaksouzian S, Zilles A, Lin G, Pankuch GA, Appelbaum PC, et al. Susceptibilities of Streptococcus pneumoniae and Haemophilus influenzae to 10 oral antimicrobial agents based on pharmacodynamic parameters: 1997 U.S. Surveillance Study. Antimicrob Agents Chemother 1999;43:1901-1908.
Gratten M, Nimmo G, Carlisle J, Schooneveldt J, Seneviratne E, Kelly R, et al. Emergence of further serotypes of multiple drug-resistant Streptococcus pneumoniae in Queensland. Commun Dis Intell 1997;21:133-136.
Arnold KE, Leggiadro RJ, Breiman RF, Lipman HB, Schwartz B, Appleton MA, et al. Risk factors for carriage of drug-resistant Streptococcus pneumoniae among children in Memphis, Tennessee. J Pediatr 1996;128:757-764.
Levine OS, Farley M, Harrison LH, Lefkowitz L, McGeer A, Schwartz B, et al. Risk factors for invasive pneumococcal disease in children: a population-based case-control study in North America. Pediatrics 1999;103:E28.
Givon-Lavi N, Dagan R, Fraser D, Yagupsky P, Porat N. Marked differences in pneumococcal carriage and resistance patterns between day care centers located within a small area. Clin Infect Dis 1999;29:1274-1280.
Black S, Shinefield H. Issues and challenges: pneumococcal vaccination in paediatrics. Paediatr Ann 1997;26:355-360.
Black SB, Shinefield HR, Hansen J, Elvin L, Laufer D, Malinoski F, et al. Postlicensure evaluation of the effectiveness of seven valent pneumococcal conjugate vaccine. Pediatr Infect Dis J 2001;20:1105-1107.
Eskola J, Kilpi T, Palmu A, Jokinen J, Haapakoski J, Herva E, et al. Efficacy of a pneumococcal conjugate vaccine against acute otitis media. N Engl J Med 2001;344:403-409.
Dagan R, Givon-Lavi N, Shkolnik L, Yagupsky P, Fraser D. Acute otitis media caused by antibiotic-resistant Streptococcus pneumoniae in southern Israel: implication for immunizing with conjugate vaccines. J Infect Dis 2000;181:1322-1329.
Shinefield H. Pneumococcal conjugate vaccines and ongoing lessons. Int J Clin Pract 2001;118 Suppl:23-25.
Dagan R, Sikuler-Cohen M, Zamir O, Janco J, Givon-Lavi N, Fraser D. Effect of a conjugate pneumococcal vaccine on the occurrence of respiratory infections and antibiotic use in day-care center attendees. Pediatr Infect Dis J 2001;20:951-958.
Information for Immunisation Providers National Childhood Pneumococcal Vaccination Program. Available from: http://www.health.gov.au/pubhlth/immunise/publications.htm. Accessed: May 2002.
Mbelle N, Huebner RE, Wasas AD, Kimura A, Chang I, Klugman KP. Immunogenicity and impact on nasopharyngeal carriage of a nonavalent pneumococcal conjugate vaccine. J Infect Dis 1999;180:1171-1176.
O'Brien KL, Bronsdon MA, Carlone GM, et al. Effect of a 7-valent pneumococcal conjugate vaccine on nasopharyngeal (NP) carriage among Navajo and White Mountain Apache (N/WMA) infants [abstract]. 19th Annual Meeting of the European Society for Paediatric Infectious Diseases 2001;22.
Dagan R, Givon S, Yagupsky P, et al. Effect of a 9-valent pneumococcal CRM197 vaccine (PncCRM9) on nasopharyngeal (NP) carriage of vaccine type and non-vaccine type S. pneumoniae (Pnc) strains among day care center (DCC) attendees (abstract). Program and Abstracts of the 38th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy 1998;299.
Obaro SK, Adegbola RA, Banya WAS, Greenwood BM. Carriage of pneumococci after pneumococcal vaccination. Lancet 1996;348:271-272.
Downloads
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2003 Communicable Diseases Intelligence
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
